US › Healthcare

Ascendis Pharma AS (ASND)

US · Healthcare · Biotechnology

$239.04-3.49%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$344.9M

Revenue YoY

+118.2%

Net profit

$210.4M

EPS

$3.29

EPS estimate

$0.78

Net margin

61.0%

EPS came in at 3.29 against a street estimate of 0.78 — a beat of 321.8%.

Key statistics

Market cap

$15.77B

P/E

18.5

Forward P/E

23.5

P/B

10.46

Book value

$25.25

EPS (TTM)

$12.97

52-week high

$282.15

52-week low

$186.05

50-day MA

$256.75

200-day MA

$233.96

Beta

0.48

Analyst view

Analysts rate Ascendis Pharma AS a strong buy (16 buy, 0 hold, 0 sell out of 16) with an average price target of $312.41.

Shareholding

Insiders

0.78%

Institutions

103.23%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	16.75%
venBio Select Advisor LLC	8.25%
FMR Inc	6.32%
Franklin Templeton Inc	3.34%
Massachusetts Financial Services Company	3.03%
BlackRock Inc	1.08%
Polar Capital Holdings PLC	1.06%
Morgan Stanley - Brokerage Accounts	0.99%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ascendis Pharma AS — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.